CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 49 enrolled
Drug / intervention
Restylane Lidocaine +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03127384
NCT03127384Phase 4Completed

A Randomised, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars

Galderma R&D·interventional·Posted Apr 25, 2017·Updated Aug 26, 2022

In Brief

A Phase 4 clinical trial evaluating Restylane Lidocaine and No-treatment control for Healthy Volunteers. Completed, enrolled 49 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate performance and safety of Restylane Lidocaine for treatment of depressed facial acne scars

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedApr 25, 2017
Enrollment StartApr 20, 2017
Primary CompletionFeb 15, 2018
Study CompletionNov 8, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.2 years ago

Interventions

Restylane Lidocainedevice

Hyaluronic acid based filler

No-treatment controlother

No-treatment control